Innovative radiopharmaceutical developers are drawing significant investment, highlighted by Actithera’s $75 million Series A funding targeting fibroblast activation protein (FAP), and Nuclidium’s $99 million Series B to advance copper isotope therapies and expand global manufacturing capabilities. These capital infusions reflect growing investor confidence in radiopharma's potential to overcome production challenges and expand therapeutic options.